Sons And Daughters Of BBCMF [BIRTH OF DIGITAL CURRENCY & BITCOINS]

[mick]

$IGEX
https://www.hulogix.com/

https://www.hulogix.com/in-production
There are multiple treatment modalities currently proposed to combat coronavirus infections. HuLogix has developed a new therapy to treat FIP (Coronavirus) in feline. Development of an inhibitor augmented response of clinical feline coronavirus infection response to a certain protease treatment.

https://www.hulogix.com/discover.html
Obesity, asthma, ocular disease, cancer and many other diseases have become epidemic. These are classified as environmental risk factor diseases by the CDC (Center for Disease Control), in that although there may be an innate genetic family risk, the ultimate eventual development of these diseases is primarily the result of environment and lifestyle. The lesson to be learned is that disease is NOT the result of “bad” genes, but rather how our genes are read. We have evolved to have our genes “read” in such a way that we were able to thrive in an environment that no longer exists, namely the African Savannah, in a physically demanding nomadic lifestyle, breathing clean air, and eating a meat and fat-based diet.

?“Epigenetics” is the study of the mechanisms that regulate how and when in our lives genes are expressed (read), which determines how we respond to environmental stressors and disease. Established medicine simply offers a “crutch” to patients afflicted with disease, that temporarily provides a chemical or modality advantage, but makes no attempt to assist the patient to more ably deal with the altered environmental risks that predisposed that patient to disease. Hulogix focuses on the epigenetic mechanisms of disease. Epigenetic Medicine is a new and powerful field of medicine that will have a huge impact on how we treat diseases in the future. We develop agents that correct these aberrant disease processes on a genetic cellular level. Hulogix has already patented and has ongoing clinical trials on several of these drugs.

https://www.hulogix.com/leadership-team.html

https://www.hulogix.com/patents.html
0358?US Non-Provisional Application for:
?
METHOD AND COMPOSITION FOR NOVEL USE OF IGF-1 AND GARCINOL TO INDUCE CLINICAL WEIGHT LOSS

Publication # US2019/0358300 A1
Publication Date: November 28, 2019

?Methods and compositions for treating patients with obesity or diabetes, or a combination thereof. Methods include administering to the patient a compound including a histone acetyltransferase inhibitor (iHAT), or an IgF-1 derivative, and a pharmaceutically acceptable carrier.

https://www.hulogix.com/newsroom.html
First Patent Approved
HuLogix is pleased to announce on November 28, 2019 the application 16/419,983, patent for clinical weight loss in animals is complete and approved.
? (Refer to patent page)

The use of IgF-1 with Garcinol is a breakthrough in weight loss. This patent also has indications in diabetes management.

"We are very excited to have our drug approved. I look forward to the clinical trials in 2020, as well as the additional drugs HuLogix currently has in the patent processing stage." CEO Martina Leon states.

https://www.hulogix.com/clinical-trials.html

[-chart]www.hulogix.com/uploads/4/6/8/2/46825901/published/depositphotos-20404851-l-2015.jpg?1566851642[/chart]



https://www.hulogix.com/under-construction.html

https://twitter.com/HuLogix?s=03